A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Overview

Journal Antibodies (Basel)

Date 2024 May 28

PMID 38804300

Authors

Corrado Zengarini

Alba Guglielmo

Martina Mussi

Giovanna Motta

Claudio Agostinelli

Elena Sabattini

Bianca Maria Piraccini

Alessandro Pileri

Affiliations

Soon will be listed here.

Abstract

The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to its role in impairing immune responses against malignant T-cells and expression profiles. Monoclonal antibodies like mogamulizumab effectively bind to CCR4, reducing tumour burden and enhancing patient outcomes by inhibiting the receptor's interaction with ligands, thereby hindering malignant T-cell migration and survival. Combining CCR4 antibodies with chemotherapy, radiation, and other drugs is being explored for synergistic effects. Additionally, small-molecular inhibitors, old pharmacological agents interacting with CCR4, and CAR-T therapies are under investigation. Challenges include drug resistance, off-target effects, and patient selection, addressed through ongoing trials refining protocols and identifying biomarkers. Despite advancements, real-life data for most of the emerging treatments are needed to temper expectations. In conclusion, CCR4-targeted therapies show promise for CTCL management, but challenges persist. Continued research aims to optimise treatments, enhance outcomes, and transform CTCL management. This review aims to elucidate the biological rationale and the several agents under various stages of development and clinical evaluation with the actual known data.

References

Kempf W, Mitteldorf C . Cutaneous T-cell lymphomas-An update 2021. Hematol Oncol. 2021; 39 Suppl 1:46-51. DOI: 10.1002/hon.2850. View

Kim Y, Bagot M, Pinter-Brown L, Rook A, Porcu P, Horwitz S . Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(9):1192-1204. DOI: 10.1016/S1470-2045(18)30379-6. View

Akpek G, Koh H, Bogen S, OHara C, Foss F . Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999; 86(7):1368-76. View

Pileri A, Morsia E, Zengarini C, Torre E, Goteri G, Quaglino P . Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region. Eur J Dermatol. 2023; 33(4):360-367. DOI: 10.1684/ejd.2023.4531. View

Laghi A, Franceschini C, Mandel V, Teoli M, Musicco F, Sansone M . Topical chlormethine gel in the treatment of mycosis fungoides: A single-center real-life experience and systematic review of the literature. Dermatol Ther. 2022; 35(9):e15683. DOI: 10.1111/dth.15683. View

Santagata S, Ierano C, Trotta A, Capiluongo A, Auletta F, Guardascione G . CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment. Front Oncol. 2021; 11:591386. PMC: 8082172. DOI: 10.3389/fonc.2021.591386. View

Mukai M, Mould D, Maeda H, Narushima K, Greene D . Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma. J Clin Pharmacol. 2019; 60(1):50-57. DOI: 10.1002/jcph.1548. View

Matsuo K, Hatanaka S, Kimura Y, Hara Y, Nishiwaki K, Quan Y . A CCR4 antagonist ameliorates atopic dermatitis-like skin lesions induced by dibutyl phthalate and a hydrogel patch containing ovalbumin. Biomed Pharmacother. 2018; 109:1437-1444. DOI: 10.1016/j.biopha.2018.10.194. View

Ishida T, Ueda R . CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci. 2006; 97(11):1139-46. PMC: 11159356. DOI: 10.1111/j.1349-7006.2006.00307.x. View

10.

Zinzani P, Quaglino P, Violetti S, Cantonetti M, Goteri G, Onida F . Critical concepts and management recommendations for cutaneous T-cell lymphoma: A consensus-based position paper from the Italian Group of Cutaneous Lymphoma. Hematol Oncol. 2021; 39(3):275-283. DOI: 10.1002/hon.2832. View

11.

Shukla L, Ajram L, Begg M, Evans B, Graves R, Hodgson S . 2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis. Eur J Med Chem. 2016; 115:14-25. DOI: 10.1016/j.ejmech.2016.02.058. View

12.

Musiek A, Rieger K, Bagot M, Choi J, Fisher D, Guitart J . Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management. Dermatol Ther (Heidelb). 2021; 12(1):29-40. PMC: 8776934. DOI: 10.1007/s13555-021-00624-7. View

13.

Narducci M, Scala E, Bresin A, Caprini E, Picchio M, Remotti D . Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood. 2005; 107(3):1108-15. DOI: 10.1182/blood-2005-04-1492. View

14.

Herschhorn A, Gu C, Espy N, Richard J, Finzi A, Sodroski J . A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat Chem Biol. 2014; 10(10):845-52. PMC: 4231716. DOI: 10.1038/nchembio.1623. View

15.

Cowan R, Scarisbrick J, Zinzani P, Nicolay J, Sokol L, Pinter-Brown L . Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. J Eur Acad Dermatol Venereol. 2021; 35(11):2225-2238. PMC: 9290719. DOI: 10.1111/jdv.17523. View

16.

Pileri Jr A, Patrizi A, Agostinelli C, Neri I, Sabattini E, Bacci F . Primary cutaneous lymphomas: a reprisal. Semin Diagn Pathol. 2011; 28(3):214-33. DOI: 10.1053/j.semdp.2011.04.002. View

17.

Geller S, Hollmann T, Horwitz S, Myskowski P, Pulitzer M . C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment. Histopathology. 2019; 76(2):222-232. PMC: 7577561. DOI: 10.1111/his.13960. View

18.

Hong D, Rixe O, Chiu V, Forde P, Dragovich T, Lou Y . Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2021; 28(3):479-488. PMC: 9401557. DOI: 10.1158/1078-0432.CCR-21-2781. View

19.

Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E . CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999; 99(1):23-33. DOI: 10.1016/s0092-8674(00)80059-8. View

20.

Kamijo H, Miyagaki T . Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol. 2021; 22(2):10. DOI: 10.1007/s11864-020-00809-w. View